RUNX1 and acute lymphoblastic leukemia: We also compared the outcomes between the two groups for final low-risk patients with ETV6-RUNX1-positive ALL or hyperdiploidy ALL who did not meet the criteria to give second dose of daunorubicin, and no significant differences were observed in terms of the 5-year event-free survival rate, the 5-year overall survival rate, the 5-year cumulative risk of any relapse, and the risk of deaths during the remission-induction phase (Supplementary Figures 1, 2).